Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 4.950-5.350 for the period, compared to the consensus EPS estimate of 5.050. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Halozyme Therapeutics Price Performance

HALO stock traded down $0.22 during mid-day trading on Thursday, reaching $57.70. 879,987 shares of the company’s stock were exchanged, compared to its average volume of 1,292,471. The company has a market cap of $7.11 billion, a price-to-earnings ratio of 16.82, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The stock’s 50 day moving average is $54.08 and its 200 day moving average is $54.71. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics has a 12-month low of $37.73 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, research analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Benchmark reaffirmed a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright increased their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock worth $1,461,001 over the last ninety days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.